This is a table of type quadgram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
quadgram | frequency |
---|---|
x x x x | 98 |
x a x a | 88 |
a x a x | 80 |
acute respiratory distress syndrome | 66 |
the study will be | 58 |
will be used to | 49 |
the end of the | 46 |
in accordance with the | 43 |
at the time of | 37 |
be included in the | 36 |
in patients with covid | 35 |
chronic obstructive pulmonary disease | 34 |
will be compared between | 32 |
will be included in | 32 |
study protocol for a | 30 |
for the treatment of | 30 |
will be used for | 30 |
neutral with regard to | 28 |
to jurisdictional claims in | 28 |
nature remains neutral with | 28 |
published maps and institutional | 28 |
springer nature remains neutral | 28 |
in published maps and | 28 |
maps and institutional affiliations | 28 |
remains neutral with regard | 28 |
regard to jurisdictional claims | 28 |
jurisdictional claims in published | 28 |
claims in published maps | 28 |
with regard to jurisdictional | 28 |
in critically ill patients | 27 |
in the control group | 27 |
the trial will be | 27 |
to participate in the | 25 |
as well as the | 25 |
a summary of the | 24 |
the primary outcome is | 24 |
acute hypoxic respiratory failure | 24 |
the intensive care unit | 24 |
and approved the final | 24 |
of the full protocol | 23 |
data will be collected | 23 |
end of the study | 23 |
note springer nature remains | 23 |
summary of the key | 22 |
accessible from the trials | 22 |
is attached as an | 22 |
the familiar formatting has | 22 |
serves as a summary | 22 |
letter serves as a | 22 |
as part of the | 22 |
familiar formatting has been | 22 |
expediting dissemination of this | 22 |
key elements of the | 22 |
the proportion of patients | 22 |
attached as an additional | 22 |
of the key elements | 22 |
as an additional file | 22 |
as a summary of | 22 |
dissemination of this material | 22 |
this letter serves as | 22 |
at the end of | 22 |
formatting has been eliminated | 22 |
the key elements of | 22 |
elements of the full | 22 |
from the trials website | 22 |
be compared between the | 22 |
patients will be randomized | 22 |
in expediting dissemination of | 21 |
any of the following | 21 |
efficacy and safety of | 21 |
interest in expediting dissemination | 21 |
the interest in expediting | 21 |
severe acute respiratory syndrome | 21 |
in the case of | 21 |
in the interest in | 21 |
the control group will | 20 |
be recorded in the | 20 |
protocol is attached as | 20 |
between the two groups | 20 |
read and approved the | 20 |
full protocol is attached | 19 |
the full protocol is | 19 |
accompanies this paper at | 19 |
authors declare that they | 19 |
they have no competing | 19 |
have no competing interests | 19 |
information accompanies this paper | 19 |
systematic review and meta | 19 |
will be asked to | 19 |
supplementary information accompanies this | 19 |
the authors declare that | 19 |
declare that they have | 19 |
that they have no | 19 |
if the patient is | 19 |
this paper at https | 19 |
numbers to be randomised | 18 |
one of the following | 18 |
a study protocol for | 18 |
inclusion and exclusion criteria | 18 |
structured summary of a | 18 |
of the study will | 18 |
randomized to ravulizumab bsc | 18 |
will be obtained from | 18 |
approved the final manuscript | 18 |
sudden sensorineural hearing loss | 17 |
summary of a study | 17 |
the use of the | 17 |
this study will be | 17 |
of a study protocol | 17 |
a structured summary of | 17 |
is based on the | 17 |
in the treatment of | 17 |
in the intensive care | 17 |
informed consent will be | 17 |
a randomised controlled trial | 17 |
will be stored in | 17 |
will be performed by | 17 |
patients randomized to ravulizumab | 17 |
compared with bsc alone | 17 |
will be conducted in | 17 |
the primary efficacy outcome | 17 |
of this study is | 17 |
analyses will be performed | 16 |
will be carried out | 16 |
the data will be | 16 |
will be performed using | 16 |
a systematic review and | 16 |
study will be conducted | 16 |
the efficacy and safety | 16 |
the design of the | 15 |
all data will be | 15 |
from the corresponding author | 15 |
protocol for a randomised | 15 |
will be analyzed using | 15 |
compared between the two | 15 |
a total of patients | 15 |
participate in the study | 15 |
continuous positive airway pressure | 15 |
time to clinical improvement | 15 |
consent will be obtained | 15 |
samples will be collected | 15 |
will have access to | 14 |
these events will be | 14 |
sequential organ failure assessment | 14 |
with the use of | 14 |
as soon as possible | 14 |
each of these events | 14 |
of these events will | 14 |
available from the corresponding | 14 |
will be recorded in | 14 |
the investigator or designee | 14 |
authors read and approved | 14 |
a randomized controlled trial | 14 |
reduce the risk of | 14 |
participation in the study | 14 |
the course of the | 14 |
the informed consent form | 14 |
the corresponding author on | 14 |
in the absence of | 14 |
of the study is | 14 |
the start of the | 14 |
analysis of the primary | 13 |
in patients with severe | 13 |
will be followed up | 13 |
no more than days | 13 |
will be reported to | 13 |
have access to the | 13 |
the results of the | 13 |
fraction of inspired oxygen | 13 |
will be randomized to | 13 |
at least one of | 13 |
within the first h | 13 |
of the study intervention | 13 |
the discretion of the | 13 |
least one of the | 13 |
twice daily for days | 13 |
all authors read and | 13 |
has been shown to | 13 |
data will be stored | 13 |
of therapy and follow | 12 |
of chronic obstructive pulmonary | 12 |
in patients with acute | 12 |
design of the study | 12 |
completion of therapy and | 12 |
will be performed in | 12 |
will be presented as | 12 |
corresponding author on reasonable | 12 |
blood samples will be | 12 |
included in the study | 12 |
author on reasonable request | 12 |
will have the option | 12 |
in the intervention group | 12 |
of the study and | 12 |
randomised controlled trial date | 12 |
the standard of care | 12 |
peking university first hospital | 12 |
for a randomised controlled | 12 |
analysis will be conducted | 12 |
the completion of therapy | 12 |
the primary evaluation period | 12 |
course of the study | 12 |
criteria for adverse events | 12 |
the study at any | 12 |
a copy of the | 12 |
patients admitted to the | 12 |
the first days after | 12 |
for the prevention of | 12 |
during the study period | 12 |
by the treating physician | 12 |
will be reported as | 12 |
the case report form | 12 |
a sample size of | 11 |
of the trial will | 11 |
at the discretion of | 11 |
be documented in the | 11 |
duration of mechanical ventilation | 11 |
the treatment of covid | 11 |
the primary and secondary | 11 |
adverse events will be | 11 |
is defined as the | 11 |
in the data analysis | 11 |
will be performed at | 11 |
any untoward medical occurrence | 11 |
study if early intervention | 11 |
secondary outcomes will be | 11 |
events will be recorded | 11 |
control group will receive | 11 |
have the option to | 11 |
analysis will be performed | 11 |
if early intervention with | 11 |
any time during the | 11 |
to the use of | 11 |
the ministry of health | 11 |
and interpretation of data | 11 |
critically ill patients with | 11 |
related to the study | 11 |
the primary outcome will | 11 |
of the trial and | 11 |
are available from the | 11 |
d proportion of patients | 11 |
be reported to the | 11 |
the duration of the | 11 |
common terminology criteria for | 11 |
terminology criteria for adverse | 11 |
will be performed on | 11 |
proportion of patients with | 11 |
this group will be | 11 |
the inclusion and exclusion | 10 |
the development of the | 10 |
to severe respiratory failure | 10 |
and institutional affiliations the | 10 |
infants hospitalised with bronchiolitis | 10 |
all analyses will be | 10 |
to evaluate the effect | 10 |
protocol for a randomized | 10 |
fondation adolphe de rothschild | 10 |
the standard protocol items | 10 |
in this study will | 10 |
a serious adverse event | 10 |
to one of the | 10 |
during the current study | 10 |
is expected to be | 10 |
subject will be included | 10 |
the declaration of helsinki | 10 |
body surface area once | 10 |
according to the following | 10 |
the patient will be | 10 |
the acute respiratory distress | 10 |
will be collected from | 10 |
patients will be recruited | 10 |
during the course of | 10 |
will be collected at | 10 |
to study if early | 10 |
to the study drug | 10 |
primary outcome will be | 10 |
mg kg twice daily | 10 |
in the active group | 10 |
will be recruited from | 10 |
la prise en charge | 10 |
study at any time | 10 |
the primary endpoint is | 10 |
duration of the study | 10 |
of the study protocol | 10 |
to standard of care | 10 |
patients with severe covid | 10 |
surface area once daily | 10 |
general data protection regulation | 10 |
at any time during | 10 |
will be recorded on | 10 |
at baseline and at | 10 |
patients in the active | 10 |
ethics committee of the | 10 |
the data monitoring committee | 10 |
will be stratified by | 10 |
evaluate the effect of | 10 |
for the primary outcome | 10 |
there will be no | 10 |
this trial will be | 10 |
the sample size calculation | 10 |
will be blinded to | 10 |
in addition to the | 10 |
will be assessed by | 10 |
in the design of | 10 |
in the case report | 9 |
m body surface area | 9 |
the nature of the | 9 |
the intervention and control | 9 |
by the investigator or | 9 |
will be analysed as | 9 |
be followed up for | 9 |
the conduct of the | 9 |
will be randomly assigned | 9 |
will be provided to | 9 |
by the study team | 9 |
after the completion of | 9 |
will be made available | 9 |
sargramostim mcg m body | 9 |
will be provided by | 9 |
is the proportion of | 9 |
a reduction in the | 9 |
until the end of | 9 |
national institutes of health | 9 |
in hospitalized patients with | 9 |
it is estimated that | 9 |
randomization will be performed | 9 |
can be found in | 9 |
be blinded to the | 9 |
analyses will be conducted | 9 |
in the first days | 9 |
proportion of patients experiencing | 9 |
the balance main trial | 9 |
on day and day | 9 |
regression will be used | 9 |
included in the data | 9 |
to the occurrence of | 9 |
for more than hours | 9 |
for the duration of | 9 |
all saes will be | 9 |
by the presence of | 9 |
will be conducted at | 9 |
mcg m body surface | 9 |
is the responsibility of | 9 |
is shown in fig | 9 |
randomized controlled trial date | 9 |
the responsibility of the | 9 |
sartre study eudract number | 9 |
ketamine will be discontinued | 9 |
access to the full | 9 |
the occurrence of each | 9 |
will be collected for | 9 |
the incidence of moderate | 9 |
the statistical analysis plan | 9 |
end of the trial | 9 |
the last infusion of | 9 |
will be collected and | 9 |
will be published in | 9 |
need for mechanical ventilation | 9 |
during the screening period | 9 |
in the event of | 9 |
for patients randomized to | 9 |
the rescue intervention strategy | 9 |
by the research team | 9 |
consent to participate in | 9 |
acute lung injury and | 9 |
at day and day | 9 |
to ensure that the | 9 |
the analysis of the | 9 |
analysed as a binary | 8 |
those who cannot take | 8 |
x a x b | 8 |
be analysed as a | 8 |
be provided by the | 8 |
will be done by | 8 |
no role in the | 8 |
in patients with ards | 8 |
data will be presented | 8 |
with acute respiratory distress | 8 |
patients under critical care | 8 |
the aim of this | 8 |
des lavages de nez | 8 |
be obtained from all | 8 |
a x b x | 8 |
will be assigned a | 8 |
hospitalised patients with covid | 8 |
proportion of patients who | 8 |
in the delivery room | 8 |
the participants will be | 8 |
be performed by the | 8 |
the current study are | 8 |
of the following criteria | 8 |
standard of care for | 8 |
in patients who at | 8 |
be obtained from the | 8 |
proactive prophylaxis with azithromycin | 8 |
the world health organization | 8 |
as a binary outcome | 8 |
part of the study | 8 |
the implementation of the | 8 |
page of alexion confidential | 8 |
a retrospective cohort study | 8 |
of cytokine release syndrome | 8 |
participate in the trial | 8 |
there is a large | 8 |
will be submitted to | 8 |
will be stored at | 8 |
with acute lung injury | 8 |
de patients ayant une | 8 |
related quality of life | 8 |
be submitted to the | 8 |
institutional affiliations the authors | 8 |
patients with acute stroke | 8 |
group will have the | 8 |
in the presence of | 8 |
university of medical sciences | 8 |
to the study intervention | 8 |
by intubated or not | 8 |
in healthcare workers with | 8 |
cox proportional hazards model | 8 |
the patient is not | 8 |
will be compared using | 8 |
of acute respiratory distress | 8 |
middle east respiratory syndrome | 8 |
de plus de points | 8 |
of each of these | 8 |
patients who at randomisation | 8 |
be informed about the | 8 |
the total number of | 8 |
with a combination of | 8 |
australia and new zealand | 8 |
to the control group | 8 |
a randomized clinical trial | 8 |
of patients will be | 8 |
mashhad university of medical | 8 |
be randomly assigned to | 8 |
primary outcome is the | 8 |
electronic case report form | 8 |
this study is to | 8 |
prophylaxis with azithromycin and | 8 |
use of the drug | 8 |
the primary endpoint will | 8 |
conduct of the study | 8 |
to provide informed consent | 8 |
on the other hand | 8 |
with acute hypoxic respiratory | 8 |
the relationship in time | 8 |
at high risk of | 8 |
intubated or not intubated | 8 |
occurrence of each of | 8 |
samples will be stored | 8 |
or not intubated on | 8 |
stratified by intubated or | 8 |
recommendations for interventional trials | 8 |
and safety monitoring board | 8 |
pourcentage de patients ayant | 8 |
for those who cannot | 8 |
will be conducted as | 8 |
will be screened for | 8 |
the severity of the | 8 |
has the potential to | 8 |
as well as a | 8 |
within days will be | 8 |
acute respiratory syndrome coronavirus | 8 |
once daily for days | 8 |
not intubated on day | 8 |
data and safety monitoring | 8 |
there are currently no | 8 |
who at randomisation were | 8 |
trial will be conducted | 8 |
primary and secondary outcomes | 8 |
the patients will be | 8 |
relationship to the study | 8 |
for at least years | 8 |
time to the occurrence | 8 |
and institutional affiliations we | 8 |
signs and symptoms of | 8 |
an adverse event which | 8 |
of the primary outcome | 8 |
will be excluded from | 8 |
it is the responsibility | 8 |
data will be analyzed | 8 |
will be informed about | 8 |
not consistent with the | 8 |
approved the final version | 8 |
that the use of | 7 |
pneumoniae and chlamydia species | 7 |
the onset of symptoms | 7 |
this is a prospective | 7 |
will be provided with | 7 |
investigator is responsible for | 7 |
sensitivity analyses will include | 7 |
study are available from | 7 |
analyzed during the current | 7 |
events will be analysed | 7 |
idiopathic sudden sensorineural hearing | 7 |
the option to receive | 7 |
to prevent one of | 7 |
for at least weeks | 7 |
on the day of | 7 |
in the crf ecrf | 7 |
and the control group | 7 |
the intervention group will | 7 |
to be completed by | 7 |
participation in the trial | 7 |
of the clinical trial | 7 |
associated with acute respiratory | 7 |
discharge from the hospital | 7 |
the trial steering committee | 7 |
of the informed consent | 7 |
an increased risk of | 7 |
days will be assigned | 7 |
days of iv sargramostim | 7 |
we would like to | 7 |
the primary analysis will | 7 |
will be assigned the | 7 |
the epidemiological impact of | 7 |
on the basis of | 7 |
is defined as any | 7 |
to assess the efficacy | 7 |
the participant will be | 7 |
and out of hospital | 7 |
conducted in accordance with | 7 |
will be limited to | 7 |
approval and consent to | 7 |
patients who die within | 7 |
in hospitalised patients with | 7 |
completion of the study | 7 |
be notified to the | 7 |
be randomized to receive | 7 |
cluster randomized controlled trial | 7 |
or until hospital discharge | 7 |
the alternative hypothesis is | 7 |
within the past months | 7 |
to renal failure requiring | 7 |
plus soc for covid | 7 |
at day will be | 7 |
patients aged years or | 7 |
respiratory distress syndrome in | 7 |
been approved by the | 7 |
as measured by the | 7 |
based on the treating | 7 |
in the study will | 7 |
american society of hematology | 7 |
the clinical recovery time | 7 |
alternative hypothesis is that | 7 |
for at least months | 7 |
in the incidence of | 7 |
primary analysis will be | 7 |
death in patients with | 7 |
for a period of | 7 |
at the same time | 7 |
will be defined as | 7 |
admitted to the icu | 7 |
sample size of patients | 7 |
were involved in the | 7 |
to severe acute respiratory | 7 |
patients in the control | 7 |
with bsc alone on | 7 |
severity of which is | 7 |
will be collected in | 7 |
the procedure will be | 7 |
on top of standard | 7 |
in the first h | 7 |
not be reported as | 7 |
free days number of | 7 |
of standard of care | 7 |
the use of a | 7 |
and no later than | 7 |
will be presented for | 7 |
informed about the study | 7 |
the effect of ravulizumab | 7 |
progression to renal failure | 7 |
x b x c | 7 |
quality of life in | 7 |
length of icu stay | 7 |
interim analysis is planned | 7 |
the patient information sheet | 7 |
will be used as | 7 |
the safety of the | 7 |
days number of days | 7 |
will be presented by | 7 |
be used to compare | 7 |
p f ratio is | 7 |
their legally acceptable representative | 7 |
of patients admitted to | 7 |
in patients under critical | 7 |
patients aged or older | 7 |
is not consistent with | 7 |
for the management of | 7 |
cluster randomised controlled trial | 7 |
prevent one of the | 7 |
ravulizumab will be administered | 7 |
will be replaced by | 7 |
and consent to participate | 7 |
the local ethics committee | 7 |
day compared with bsc | 7 |
ethics approval and consent | 7 |
the ae crf ecrf | 7 |
is one of the | 7 |
standard of care and | 7 |
invasive mechanical ventilatory support | 7 |
be recorded on the | 7 |
for the development of | 7 |
at least years of | 7 |
who die within days | 7 |
within the first days | 7 |
intervention to prevent one | 7 |
alive and out of | 7 |
during the first days | 7 |
the intervention will be | 7 |
study will be performed | 7 |
up visits will be | 7 |
before the start of | 7 |
aged years or older | 7 |
as a result of | 7 |
as part of a | 7 |
the first h of | 7 |
effect of iloprost on | 7 |
to the intervention arm | 7 |
involved in the study | 7 |
or the control group | 7 |
die within days will | 7 |
be stored in a | 7 |
the p f ratio | 7 |
of the primary endpoint | 7 |
first h of life | 7 |
will be randomized in | 7 |
jun page of alexion | 7 |
for critically ill patients | 7 |
in the live home | 7 |
withdraw from the study | 7 |
after the end of | 7 |
to assess the effect | 7 |
of the declaration of | 7 |
between the intervention and | 7 |
of the primary efficacy | 7 |
and quality of life | 7 |
top of standard of | 7 |
progressing to severe respiratory | 7 |
be assigned the value | 7 |
renal failure requiring dialysis | 7 |
high risk of sars | 6 |
additional days of iv | 6 |
for mortality of adult | 6 |
is a large number | 6 |
hypoxic respiratory failure to | 6 |
confirmed by recent laboratory | 6 |
of treatment success after | 6 |
was approved by the | 6 |
have a huge impact | 6 |
the investigator is responsible | 6 |
will be called group | 6 |
of severe acute respiratory | 6 |
twice daily for those | 6 |
will be conducted on | 6 |
with standard supportive care | 6 |
discharged from the hospital | 6 |
from the study at | 6 |
of versus days of | 6 |
will be based on | 6 |
stored in a secure | 6 |
wilcoxon rank sum test | 6 |
and maximal increase in | 6 |
be approved by the | 6 |
when the patient is | 6 |
patients randomised to the | 6 |
outcome and as a | 6 |
in the prep group | 6 |
in the united states | 6 |
of the icu units | 6 |
evaluate differences in the | 6 |
for the analysis of | 6 |
group will receive an | 6 |
be provided to the | 6 |
icu admission or death | 6 |
in the critical care | 6 |
during the intervention period | 6 |
of the primary evaluation | 6 |
that are currently being | 6 |
to study if treatment | 6 |
of lost to follow | 6 |
day intervention with sargramostim | 6 |
and risk factors for | 6 |
and acute respiratory distress | 6 |
trial is funded by | 6 |
for the use of | 6 |
the trial master file | 6 |
untoward medical occurrence that | 6 |
patients will be included | 6 |
the study has been | 6 |
but not limited to | 6 |
adult inpatients with covid | 6 |
intervention with inhaled sargramostim | 6 |
foreseeable overflow of the | 6 |
all serious adverse events | 6 |
at day compared with | 6 |
will be left to | 6 |
to give access to | 6 |
during the completion of | 6 |
will be approved by | 6 |
day period is reached | 6 |
will be generated by | 6 |
the inclusion criteria are | 6 |
the pao fio ratio | 6 |
until the day period | 6 |
least years of age | 6 |
on the foreseeable overflow | 6 |
of ravulizumab bsc compared | 6 |
clinical course and risk | 6 |
mortality of adult inpatients | 6 |
serious adverse event on | 6 |
patients will be enrolled | 6 |
en lavage de nez | 6 |
for the purpose of | 6 |
or analyzed during the | 6 |
or legally acceptable representative | 6 |
peripheral capillary oxygen saturation | 6 |
and as a time | 6 |
hospitalized patients with covid | 6 |
patients that are currently | 6 |
be conducted at the | 6 |
the primary endpoint of | 6 |
will be in the | 6 |
will be responsible for | 6 |
to evaluate differences in | 6 |
obtained from all participants | 6 |
study data will be | 6 |
plus de points au | 6 |
indigenous infants hospitalised with | 6 |
huge impact on the | 6 |
be analyzed using a | 6 |
event on or before | 6 |
at a dose of | 6 |
between day and day | 6 |
receive an additional days | 6 |
b x c x | 6 |
early intervention with inhaled | 6 |
will be administered intravenously | 6 |
at least weeks after | 6 |
studies have shown that | 6 |
or their legally acceptable | 6 |
in patients with sars | 6 |
patients in the icu | 6 |
be randomized in a | 6 |
risk factors for mortality | 6 |
the foreseeable overflow of | 6 |
impact on the foreseeable | 6 |
will be invited to | 6 |
for at least days | 6 |
acutely ill medical patients | 6 |
in medical patients with | 6 |
targeted indoor residual spraying | 6 |
patients will be randomly | 6 |
the number of days | 6 |
study if treatment with | 6 |
in the northern territory | 6 |
summary of product characteristics | 6 |
in the study design | 6 |
after the onset of | 6 |
current study are available | 6 |
to receive an additional | 6 |
overflow of the icu | 6 |
the opinion of the | 6 |
and will not be | 6 |
points au score odoratest | 6 |
we will use the | 6 |
be collected at baseline | 6 |
bsc compared with bsc | 6 |
with the help of | 6 |
primary and secondary endpoints | 6 |
respiratory failure to ards | 6 |
to assess the safety | 6 |
the subject or legally | 6 |
the national institutes of | 6 |
if a patient is | 6 |
to evaluate the efficacy | 6 |
the study by the | 6 |
maximal value and maximal | 6 |
being hospitalized across the | 6 |
patients will be asked | 6 |
for ten days or | 6 |
if treatment with sargramostim | 6 |
of days within the | 6 |
will be presented in | 6 |
option to receive an | 6 |
will be kept in | 6 |
suspected unexpected serious adverse | 6 |
are eligible for inclusion | 6 |
large number of covid | 6 |
below on minimal l | 6 |
or before d proportion | 6 |
be left to the | 6 |
compared to standard of | 6 |
infected patients that are | 6 |
analysis and interpretation of | 6 |
the study intervention or | 6 |
signs of cytokine release | 6 |
increase the risk of | 6 |
subject or legally acceptable | 6 |
the beginning of the | 6 |
participation in this study | 6 |
of which is not | 6 |
for a randomized controlled | 6 |
must be informed that | 6 |
imv in patients who | 6 |
within days of the | 6 |
effect of ravulizumab bsc | 6 |
to the administration of | 6 |
a huge impact on | 6 |
used to assess the | 6 |
and designed the study | 6 |
to the full protocol | 6 |
version to be published | 6 |
patients with acute hypoxic | 6 |
the study should be | 6 |
in elderly patients with | 6 |
to the development of | 6 |
before d proportion of | 6 |
at randomisation were in | 6 |
intermittent positive pressure ventilation | 6 |
a large number of | 6 |
specified in the soa | 6 |
course and risk factors | 6 |
we are conducting a | 6 |
the study and the | 6 |
weeks prior to randomization | 6 |
median and interquartile range | 6 |
first days after enrollment | 6 |
will be calculated for | 6 |
in patients treated with | 6 |
by recent laboratory test | 6 |
on or before d | 6 |
experiencing a serious adverse | 6 |
acute exacerbation of copd | 6 |
associated with the use | 6 |
the results of this | 6 |
reduction in the incidence | 6 |
factors for mortality of | 6 |
as specified in the | 6 |
the university of oxford | 6 |
x c x x | 6 |
assess the safety of | 6 |
are currently being hospitalized | 6 |
patients included in the | 6 |
withdrawn from the study | 6 |
the cure rct is | 6 |
the administration of the | 6 |
ravulizumab bsc compared with | 6 |
daily for those who | 6 |
to withdraw from the | 6 |
in the treatment group | 6 |
with the exception of | 6 |
model will be used | 6 |
will be done using | 6 |
the vast majority of | 6 |
the balance main rct | 6 |
the day period is | 6 |
included in the trial | 6 |
pwds and their caregivers | 6 |
for early breast cancer | 6 |
provided with standard supportive | 6 |
the study intervention and | 6 |
to take part in | 6 |
to the intensive care | 6 |
patients in each group | 6 |
medical ethics committee of | 6 |
progressive patients in the | 6 |
and days of enrolment | 6 |
exacerbations of chronic obstructive | 6 |
currently being hospitalized across | 6 |
au cours de la | 6 |
becoming aware of the | 6 |
in adult patients with | 6 |
the study physician will | 6 |
analyses will be done | 6 |
current standard of care | 6 |
must be recorded in | 6 |
primary endpoint will be | 6 |
any hospitalization or all | 6 |
adverse event on or | 6 |
detailed statistical analysis plan | 6 |
number of days within | 6 |
the trial was registered | 6 |
nasal continuous positive airway | 6 |
participants will be recruited | 6 |
de points au score | 6 |
randomized controlled trial of | 6 |
between d and d | 6 |
who cannot take oral | 6 |
as determined by the | 6 |
will be determined by | 6 |
value and maximal increase | 6 |
a binary outcome and | 6 |
which is not consistent | 6 |
is anticipated to be | 6 |
iv twice daily for | 6 |
in the context of | 6 |
with standard hygiene requirements | 6 |
ards could have a | 6 |
group will be called | 6 |
patients enrolled in the | 6 |
by the use of | 6 |
of patients experiencing a | 6 |
of lopinavir ritonavir and | 6 |
will not be reported | 6 |
based dose of ravulizumab | 6 |
days within the first | 6 |
the aim of the | 6 |
of synbiotic supplementation on | 6 |
as the date of | 6 |
a cluster randomised controlled | 6 |
recorded in the case | 6 |
will be summarized by | 6 |
might be due to | 6 |
hospitalized across the globe | 6 |
active group will have | 6 |
categorical variables will be | 6 |
at the university of | 6 |
an ae or sae | 6 |
eligibility criteria for the | 6 |
a member of the | 6 |
will be given to | 6 |
assess the efficacy of | 6 |
start of the study | 6 |
an additional days of | 6 |
patients experiencing a serious | 6 |
intravenously following this posology | 6 |
be due to the | 6 |
of adult inpatients with | 6 |
relationship in time is | 6 |
on minimal l min | 6 |
binary outcome and as | 6 |
test will be used | 6 |
could have a huge | 6 |
the active group will | 6 |
sharing is not applicable | 6 |
mean and standard deviation | 6 |
group and the control | 5 |
will be calculated by | 5 |
in mechanically ventilated patients | 5 |
datasets were generated or | 5 |
on the use of | 5 |
of the following events | 5 |
not related to the | 5 |
free of mechanical ventilation | 5 |
ascending part of the | 5 |
biological specimens for genetic | 5 |
patients do not receive | 5 |
with numbers of patients | 5 |
be informed that their | 5 |
ketamine infusion as an | 5 |
administration of the study | 5 |
the primary objective is | 5 |
for patients who are | 5 |
fentanyl and or midazolam | 5 |
there is an urgent | 5 |
length of stay in | 5 |
by the ministry of | 5 |
the need for intubation | 5 |
provide written informed consent | 5 |
participants will be asked | 5 |
enrolled in the trial | 5 |
will be followed until | 5 |
data will be used | 5 |
of the intervention to | 5 |
continued from previous page | 5 |
when patients do not | 5 |
parallel group randomised trials | 5 |
and new zealand clinical | 5 |
can be used as | 5 |
hiruz ctu will submit | 5 |
will be included as | 5 |
of vestibular function tests | 5 |
the conclusion of the | 5 |
as defined by the | 5 |
reduce the incidence of | 5 |
in a cohort of | 5 |
the current proposed protocol | 5 |
australian institute of health | 5 |
patient safety information card | 5 |
over a period of | 5 |
dietary quality and pa | 5 |
give access to the | 5 |
at the level of | 5 |
in the experimental group | 5 |
enrollment when patients do | 5 |
sargramostim will be replaced | 5 |
will be no shortage | 5 |
involved in the design | 5 |
and the presence of | 5 |
which a significant portion | 5 |
study participants will be | 5 |
in the setting of | 5 |
ctu will submit to | 5 |
of care in the | 5 |
samples will be drawn | 5 |
early intervention with sargramostim | 5 |
missing data will be | 5 |
the treatment of ards | 5 |
as well as for | 5 |
reduce the need for | 5 |
or molecular analysis in | 5 |
the applicable product information | 5 |
within the last days | 5 |
the decision to submit | 5 |
is responsible for the | 5 |
chez les patients covid | 5 |
to the berlin definition | 5 |
but are not limited | 5 |
lopinavir ritonavir and interferon | 5 |
are not limited to | 5 |
major clinically relevant bleeding | 5 |
current ascending part of | 5 |
copd gold c d | 5 |
consistent with the applicable | 5 |
last infusion of study | 5 |
the secondary outcomes include | 5 |
for the presence of | 5 |
trial was registered on | 5 |
vous aviez avant le | 5 |
of venous thromboembolism in | 5 |
hospital of fudan university | 5 |
during the procedure will | 5 |
total sample size is | 5 |
role in the design | 5 |
part of the epidemiology | 5 |
of the clinical study | 5 |
access to the final | 5 |
in collaboration with the | 5 |
of critically ill patients | 5 |
days of antibiotic treatment | 5 |
the total duration of | 5 |
prise en charge de | 5 |
important protocol amendments to | 5 |
in severe trauma patients | 5 |
liver and kidney function | 5 |
to the study team | 5 |
be administered intravenously following | 5 |
h ketamine will be | 5 |
azithromycin and chloroquine in | 5 |
the number of patients | 5 |
in the source documents | 5 |
in view of the | 5 |
under severe air pollution | 5 |
later than calendar days | 5 |
be in accordance with | 5 |
standard of care alone | 5 |
proportion of patients progressing | 5 |
be no shortage of | 5 |
deviations from the protocol | 5 |
preventing the fatal consequences | 5 |
will be administered on | 5 |
in patients in the | 5 |
this is a single | 5 |
has been used for | 5 |
according to the berlin | 5 |
shortage of patients that | 5 |
applicable to this article | 5 |
replaced by intravenous sargramostim | 5 |
presence of elevated il | 5 |
obtained from the subject | 5 |
as the primary outcome | 5 |
low birth weight infants | 5 |
amendments to relevant parties | 5 |
registry of clinical trials | 5 |
plans to give access | 5 |
and or fentanyl and | 5 |
genetic or molecular analysis | 5 |
requiring dialysis at day | 5 |
no shortage of patients | 5 |
of this intervention is | 5 |
risk of asthma exacerbations | 5 |
the fatal consequences of | 5 |
part of a clinical | 5 |
updated guidelines for reporting | 5 |
the health of the | 5 |
due to the nature | 5 |
the medical ethics committee | 5 |
patients admitted to hospital | 5 |
cancer specialists and gps | 5 |
the trial has been | 5 |
with sarilumab at the | 5 |
the same doses and | 5 |
the progression from manageable | 5 |
at the study center | 5 |
conceived and designed the | 5 |
alexion within hours of | 5 |
will be asked for | 5 |
adult patients admitted to | 5 |
and chloroquine in hospitalised | 5 |
department of health and | 5 |
will also be reported | 5 |
will be required to | 5 |
on the management of | 5 |
and rising since last | 5 |
reported to the sponsor | 5 |
and chronic health evaluation | 5 |
risk factors associated with | 5 |
in the event that | 5 |
blinded to group assignment | 5 |
mg orally twice daily | 5 |
plans for communicating important | 5 |
of the university hospital | 5 |
patients with confirmed covid | 5 |
in the evidence of | 5 |
trial of versus days | 5 |
will be protected by | 5 |
ghent university hospital has | 5 |
within the day period | 5 |
the protocol will be | 5 |
will be considered as | 5 |
with inhaled sargramostim affects | 5 |
this study aims to | 5 |
results of the study | 5 |
need for intubation and | 5 |
plot will be presented | 5 |
patients have completed the | 5 |
elderly patients with acute | 5 |
will receive mg ravulizumab | 5 |
like to acknowledge the | 5 |
in the proportion of | 5 |
for the following variables | 5 |
the final version of | 5 |
bubonic or pneumonic plague | 5 |
and death in patients | 5 |
by the principal investigator | 5 |
consent will be taken | 5 |
to assess the impact | 5 |
whether the patient has | 5 |
showing more than organ | 5 |
new zealand clinical trials | 5 |
admitted to the hospital | 5 |
do not receive of | 5 |
or fentanyl and or | 5 |
than days after the | 5 |
in the definition of | 5 |
patients progressing to severe | 5 |
nasal intermittent positive pressure | 5 |
hypoxic respiratory failure and | 5 |
be discussed with the | 5 |
be carried out in | 5 |
used in clinical practice | 5 |
the mean number of | 5 |
up to mg kg | 5 |
admitted to one of | 5 |
acceptable representative will be | 5 |
in the opinion of | 5 |
inhaled sargramostim will be | 5 |
notified to the sponsor | 5 |
than or equal to | 5 |
as part of routine | 5 |
with azithromycin and chloroquine | 5 |
statistical analyses will be | 5 |
is not applicable to | 5 |
that given the current | 5 |
results of this study | 5 |
ward at ghent university | 5 |
and days of randomization | 5 |
of a clinical study | 5 |
the risk of asthma | 5 |
will be randomized using | 5 |
to the nature of | 5 |
for up to days | 5 |
in the management of | 5 |
all participants will be | 5 |
patients with acute respiratory | 5 |
included in this study | 5 |
analysis in this trial | 5 |
and trial steering committee | 5 |
composition of the data | 5 |
will be evaluated by | 5 |
chronic suppurative lung disease | 5 |
and reporting structure a | 5 |
with the standard protocol | 5 |
be performed at the | 5 |
data will be available | 5 |
total and free c | 5 |
the first year of | 5 |
physiology and chronic health | 5 |
respiratory and multi organ | 5 |
patients will receive mg | 5 |
between the specialist cancer | 5 |
no datasets were generated | 5 |
reported as an ae | 5 |
is not related to | 5 |
of peripheral vestibular function | 5 |
will be used in | 5 |
for the current proposed | 5 |
certainty in the evidence | 5 |
numbers of patients rising | 5 |
consolidated standards of reporting | 5 |
on the role of | 5 |
a legally acceptable representative | 5 |
will be randomly allocated | 5 |
data safety monitoring board | 5 |
guidelines for reporting parallel | 5 |
the required sample size | 5 |
entre les deux bras | 5 |
randomization will be stratified | 5 |
at the beginning of | 5 |
relating to the study | 5 |
for genetic or molecular | 5 |
discretion of the treating | 5 |
x b x x | 5 |
to submit the report | 5 |
clinical recovery time of | 5 |
use of the study | 5 |
be collected at the | 5 |
the ethics committee of | 5 |
time during the study | 5 |
safety outcomes will be | 5 |
single mg sarilumab dose | 5 |
the first h after | 5 |
data sharing is not | 5 |
hospital has admitted confirmed | 5 |
of mashhad university of | 5 |
standard of care in | 5 |
provided in the study | 5 |
experimental and control groups | 5 |
molecular analysis in this | 5 |
heart failure nyha iii | 5 |
submit the report for | 5 |
procedure will be compared | 5 |
defined by the presence | 5 |
to initiate iv sargramostim | 5 |
final version of the | 5 |
min after the injection | 5 |
minimal l min o | 5 |
is to assess the | 5 |
all patients will be | 5 |
containing mg sarilumab in | 5 |
data safety and monitoring | 5 |
groups will be compared | 5 |
dental pulp stem cells | 5 |
reporting parallel group randomised | 5 |
will be performed for | 5 |
of the eminent intervention | 5 |
of patients progressing to | 5 |
will be maintained by | 5 |
for preventing the fatal | 5 |
nature or severity of | 5 |
will be calculated using | 5 |
to the central ec | 5 |
with a deviated septum | 5 |
consist of the following | 5 |
intervention and control groups | 5 |
b x x x | 5 |
has admitted confirmed cases | 5 |
partial pressure of oxygen | 5 |
given the current ascending | 5 |
evaluate the efficacy and | 5 |
of the epidemiology curve | 5 |
to the study design | 5 |
patients or their legally | 5 |
and for at least | 5 |
will be filled out | 5 |
chloroquine in hospitalised patients | 5 |
to the control arm | 5 |
for indoor residual spraying | 5 |
will be sent to | 5 |
days after enrollment when | 5 |
the primary outcome measure | 5 |
secondary endpoints will be | 5 |
with respect to the | 5 |
legally acceptable representative will | 5 |
when all patients have | 5 |
with dementia and their | 5 |
be replaced by intravenous | 5 |
patients will be followed | 5 |
will be allocated to | 5 |
administered intravenously following this | 5 |
the k th stage | 5 |
written informed consent will | 5 |
upon progression of disease | 5 |
for reporting parallel group | 5 |
infusion of study drug | 5 |
more than organ failure | 5 |
the role of the | 5 |
the common terminology criteria | 5 |
outcomes in patients with | 5 |
at d proportion of | 5 |
and statistical code c | 5 |
rising since last h | 5 |
institute of health and | 5 |
the international conference on | 5 |
study physician at each | 5 |
the local principal investigator | 5 |
in this trial future | 5 |
of which a significant | 5 |
prep group compared to | 5 |
no treatments directed at | 5 |
day for all patients | 5 |
admission to the icu | 5 |
by the ethics committee | 5 |
randomised controlled trial of | 5 |
interim analysis will be | 5 |
believe that given the | 5 |
the nature or severity | 5 |
of the interim analysis | 5 |
in terms of the | 5 |
blood sample will be | 5 |
que vous aviez avant | 5 |
the data protection act | 5 |
therefore believe that given | 5 |
the outcome of the | 5 |
as defined in section | 5 |
patients with coronavirus disease | 5 |
associated with complement activation | 5 |
storage of biological specimens | 5 |
to ards could have | 5 |
be rescued with sarilumab | 5 |
identifying information will be | 5 |
propofol and or fentanyl | 5 |
support within the day | 5 |
versus days of antibiotic | 5 |
in the ae crf | 5 |
severe acute respiratory distress | 5 |
and multi organ failure | 5 |
after enrollment when patients | 5 |
will be documented in | 5 |
will also be performed | 5 |
sarilumab at the same | 5 |
be performed in the | 5 |
the objectives of the | 5 |
withdraw from the trial | 5 |
meier plot will be | 5 |
will be performed according | 5 |
while breathing room air | 5 |
in acutely ill medical | 5 |
of patients with covid | 5 |
a combination of lopinavir | 5 |
is supported by a | 5 |
la fondation adolphe de | 5 |
of the data monitoring | 5 |
this is an open | 5 |
the report for publication | 5 |
communicating important protocol amendments | 5 |
area once daily for | 5 |
the difference between the | 5 |
statistical analysis plan for | 5 |
the feasibility of the | 5 |
this trial future use | 5 |
first days after stroke | 5 |
patients infected with covid | 5 |
and recruitment is ongoing | 5 |
not applicable to this | 5 |
the cure rct will | 5 |
university hospital has admitted | 5 |
of prep with hydroxychloroquine | 5 |
the sponsor is responsible | 5 |
of the study as | 5 |
of biological specimens for | 5 |
failure requiring dialysis at | 5 |
are currently no treatments | 5 |
will not be possible | 5 |
study is to evaluate | 5 |
treatment with ravulizumab bsc | 5 |
of bronchiolitis in indigenous | 5 |
indicated in the soa | 5 |
may be due to | 5 |
causal relationship to the | 5 |
the study physician at | 5 |
of health and welfare | 5 |
as there is no | 5 |
currently no treatments directed | 5 |
at the same doses | 5 |
will be able to | 5 |
be found in the | 5 |
from the time of | 5 |
a positive test for | 5 |
impliquant la personne humaine | 5 |
in the reference group | 5 |
participated in its design | 5 |
physician at each site | 5 |
we therefore believe that | 5 |
enrolled in the study | 5 |
that treatment with ravulizumab | 5 |
is to evaluate the | 5 |
changes to the protocol | 5 |
sodium chloride for a | 5 |
effects of iloprost on | 5 |
meet the criteria for | 5 |
will be stored for | 5 |
criteria for the current | 5 |
specimens for genetic or | 5 |
protocol amendments to relevant | 5 |
acute physiology and chronic | 5 |
reliability of ctcae ratings | 5 |
patients that are eligible | 5 |
the prep group compared | 5 |
the main secondary outcome | 5 |
will continue to be | 5 |
is discharged from the | 5 |
rescued with sarilumab at | 5 |
at ghent university hospital | 5 |
last infusion of ravulizumab | 5 |
on the same day | 5 |
for communicating important protocol | 5 |
the investigator will be | 5 |
will be considered to | 5 |
the current ascending part | 5 |
and storage of biological | 5 |
is defined as a | 5 |
in writing the manuscript | 5 |
the sample size and | 5 |
approved by the ethics | 5 |
the sponsor and the | 5 |
or severity of which | 5 |
the study design and | 5 |
days free of mechanical | 5 |
kidney and liver function | 5 |
in just days time | 5 |
data will also be | 5 |
days alive and out | 5 |
and drafted the manuscript | 5 |
primary endpoint is the | 5 |
patients who meet the | 5 |
resource utilization in dementia | 5 |
in ventilated trauma patients | 5 |
saturation below on minimal | 5 |
is that treatment with | 5 |
hypothesis is that treatment | 5 |
olfactives que vous aviez | 5 |
will consist of the | 5 |
in the trial will | 5 |
low certainty in the | 5 |
the risk of developing | 5 |
methylprednisolone mg kg day | 5 |
the effects of iloprost | 5 |
be given to the | 5 |
be sent to the | 5 |
kg twice daily for | 5 |
no later than calendar | 5 |
in the study and | 5 |
primary objective is to | 5 |
as no datasets were | 5 |
ent hospital of fudan | 5 |
aim of this study | 5 |
assess the impact of | 5 |
eligible patients will be | 5 |
fatal consequences of acute | 5 |
be asked to sign | 5 |
will be measured by | 5 |
with ravulizumab bsc will | 5 |
of patients rising sharply | 5 |
will submit to the | 5 |
patients showing more than | 5 |
of patients that are | 5 |
is an urgent need | 5 |
of patients who are | 5 |
with the applicable product | 5 |
results will be reported | 5 |
of the research team | 5 |
of the intervention will | 4 |
based on the results | 4 |
air pollution monitoring station | 4 |
will be recorded and | 4 |
arterial blood gas determination | 4 |
as described in the | 4 |
in the study database | 4 |
decision to submit the | 4 |
functional assessment of cancer | 4 |
guidelines for management of | 4 |
prior to initiating ravulizumab | 4 |
against placebo in healthcare | 4 |
area once daily until | 4 |
change from baseline in | 4 |
or invasive mechanical ventilation | 4 |
lavage de nez sera | 4 |
in addition to these | 4 |
accordance with the standard | 4 |
are described in the | 4 |
for inclusion in the | 4 |
stored samples will be | 4 |
be administered on day | 4 |
event which might be | 4 |
part of the trial | 4 |
signature of the informed | 4 |
to handle missing data | 4 |
we anticipate that the | 4 |
involved in data collection | 4 |
and the use of | 4 |
in the study at | 4 |
will be transferred to | 4 |
released to the participating | 4 |
the timepoints indicated in | 4 |
receiving satisfying responses to | 4 |
the proposed intervention is | 4 |
and safety of sarilumab | 4 |
in two consecutive blood | 4 |
statistical analysis will be | 4 |
the patients in the | 4 |
that may affect the | 4 |
the relative stress scale | 4 |
of asthma exacerbations per | 4 |
an electronic randomization will | 4 |
all patients who are | 4 |
be screened for eligibility | 4 |
premature termination of the | 4 |
the presence of any | 4 |
will be released to | 4 |
option to initiate iv | 4 |
the patient safety information | 4 |
of the clinical team | 4 |
used as part of | 4 |
with blinded outcome assessment | 4 |
of days free of | 4 |
ray and or ct | 4 |
and exclusion criteria are | 4 |
data will be checked | 4 |
les patients du groupe | 4 |
practice in the live | 4 |
in analysis to handle | 4 |
a final concentration of | 4 |
in severe acute respiratory | 4 |
presence or absence of | 4 |
asking questions and receiving | 4 |
for measuring blood cytokine | 4 |
the miracle trial is | 4 |
receive jwby formulas plus | 4 |
institutional affiliations we would | 4 |
the data safety and | 4 |
is defined as an | 4 |
the risk of non | 4 |
on how to administer | 4 |
the patient information and | 4 |
the institutional review board | 4 |
described in this protocol | 4 |
a total of subjects | 4 |
in practice in the | 4 |
censored in the case | 4 |
the purpose of this | 4 |
stable chronic obstructive pulmonary | 4 |
new zealand clinical trial | 4 |
have been approved by | 4 |
included in an open | 4 |
ravulizumab for patients randomized | 4 |
is in the best | 4 |
will occur in the | 4 |
be released to the | 4 |
a detailed description of | 4 |
the ovid study will | 4 |
be used to identify | 4 |
of septoplasty versus medical | 4 |
and is expected to | 4 |
the type i error | 4 |
are enrolled in the | 4 |
been shown to reduce | 4 |
the study was approved | 4 |
once daily until the | 4 |
hospital and research center | 4 |
of bronchiectasis exacerbations in | 4 |
kg iv twice daily | 4 |
has been approved by | 4 |
the total sample size | 4 |
responses to all questions | 4 |
clinical presentation consistent with | 4 |
standard of care treatment | 4 |
the patient is discharged | 4 |
the exception of the | 4 |
will be assessed using | 4 |
in patients with a | 4 |
adult respiratory distress syndrome | 4 |
a fourfold increase in | 4 |
be used as a | 4 |
fio fraction of inspired | 4 |
reducing their risk of | 4 |
entry to the study | 4 |
would lead to improved | 4 |
induced acute lung injury | 4 |
at least months from | 4 |
consent to participate will | 4 |
anticipated to be completed | 4 |
conclusion of the study | 4 |
the use of budesonide | 4 |
treating physician will have | 4 |
and before entry to | 4 |
healthcare workers with negative | 4 |
collected for measuring blood | 4 |
timepoints indicated in the | 4 |
of unplanned outpatient visits | 4 |
and activation of immune | 4 |
the study is to | 4 |
conduct of the trial | 4 |
to versus days of | 4 |
a significance level of | 4 |
both treatment groups will | 4 |
this is a hospital | 4 |
of the effects of | 4 |
within days of randomization | 4 |
moderate to severe ards | 4 |
start of the trial | 4 |
logistic regression will be | 4 |
in case of progression | 4 |
an accompanying person from | 4 |
used in this trial | 4 |
trial will be published | 4 |
a clinical presentation consistent | 4 |
by a member of | 4 |
be censored in the | 4 |
approximately patients will be | 4 |
pwd and the caregiver | 4 |
be maintained by the | 4 |
ketamine will be continued | 4 |
study intervention caused the | 4 |
will be analyzed as | 4 |
all adult patients admitted | 4 |
handle missing data c | 4 |
best of our knowledge | 4 |
for both types of | 4 |
data safety monitoring committee | 4 |
development and validation of | 4 |
of the exclusion criteria | 4 |
for patients randomized and | 4 |
international conference on harmonisation | 4 |
hospitals and two large | 4 |
x x x b | 4 |
in patients with dementia | 4 |
assessment of cancer therapy | 4 |
for management of venous | 4 |
ratio of pao fio | 4 |
with azithromycin and hydroxychloroquine | 4 |
combination with the log | 4 |
is considered to be | 4 |
skills to support behaviour | 4 |
a deviated nasal septum | 4 |
analysis or interpretation of | 4 |
to the protocol will | 4 |
features of secondary haemophagocytic | 4 |
the intervention clinician will | 4 |
to the best of | 4 |
be used in this | 4 |
size calculation is based | 4 |
deemed clinically appropriate by | 4 |
antibiotic prophylaxis for at | 4 |
endpoint is the proportion | 4 |
as described in this | 4 |
receive standard of care | 4 |
fio and through measurement | 4 |
global burden of disease | 4 |
ards in patients with | 4 |
china clinical course and | 4 |
we will assess the | 4 |
or mg kg iv | 4 |
about the study by | 4 |
primary endpoint of this | 4 |
days or until hospital | 4 |
model for breast cancer | 4 |
of discharge from hospital | 4 |
to treat patients with | 4 |
by intravenous sargramostim mcg | 4 |
be filed in the | 4 |
should continue antibiotic prophylaxis | 4 |
time to resolution of | 4 |
test for two independent | 4 |
and any statistical methods | 4 |
be removed from the | 4 |
with an endotracheal tube | 4 |
quality of life group | 4 |
the control group and | 4 |
after treatment with the | 4 |
single iv injection on | 4 |
she will be considered | 4 |
the safety and efficacy | 4 |
is estimated to be | 4 |
that a causal relationship | 4 |
as a nebulized inhalation | 4 |
endpoint of this intervention | 4 |
termination of the trial | 4 |
to considerer the trial | 4 |
for breast cancer survivors | 4 |
if the patient has | 4 |
should be considered in | 4 |
mg methylprednisolone or equivalent | 4 |
and no exclusion criteria | 4 |
period of mechanical ventilation | 4 |
of respiratory exacerbations by | 4 |
if the patient does | 4 |
will be notified to | 4 |
the case of a | 4 |
measurement of the p | 4 |
the quintet recruitment intervention | 4 |
the primary end point | 4 |
in this group will | 4 |
will be recorded as | 4 |
will be performed to | 4 |
dose ketamine infusion as | 4 |
visits will be conducted | 4 |
having received sufficient time | 4 |
all adverse events will | 4 |
the entire study period | 4 |
manageable acute hypoxic respiratory | 4 |
and through measurement of | 4 |
relationship between the study | 4 |
which might be due | 4 |
recorded on the ae | 4 |
days of antibiotics for | 4 |
patients who are randomized | 4 |
defined as the date | 4 |
in patients with copd | 4 |
to an investigational medicinal | 4 |
secondary outcomes include the | 4 |
mg kg iv twice | 4 |
french ministry of health | 4 |
admitted to the intensive | 4 |
the closest study center | 4 |
is voluntary and that | 4 |
to oral administration once | 4 |
in reducing their risk | 4 |
up in healthcare workers | 4 |
after admission to the | 4 |
an untoward medical occurrence | 4 |
must use a condom | 4 |
of ravulizumab for patients | 4 |
should receive prophylactic antibiotics | 4 |
medical occurrence in a | 4 |
the coordinating principle investigator | 4 |
standard of care has | 4 |
and will be performed | 4 |
white blood cell count | 4 |
the summary of product | 4 |
hydroxychloroquine against placebo in | 4 |
ravulizumab bsc will improve | 4 |
to any of the | 4 |
according to french law | 4 |
interpretation of data and | 4 |
be collected for measuring | 4 |
duration of icu stay | 4 |
details of the study | 4 |
to handle protocol non | 4 |
prior to the day | 4 |
puncture will be taken | 4 |
confirmed diagnosis of sars | 4 |
treatment effects will be | 4 |
data will be handled | 4 |
to support behaviour change | 4 |
which is defined as | 4 |
and diversity of respiratory | 4 |
the application of a | 4 |
within hours after becoming | 4 |
is conducted in accordance | 4 |
in which patients are | 4 |
will be informed that | 4 |
intervention group will receive | 4 |
acute respiratory and multi | 4 |
data will be entered | 4 |
the time of submission | 4 |
treatment with sargramostim affects | 4 |
safety and efficacy of | 4 |
in the balance main | 4 |
control group will be | 4 |
analysis to handle protocol | 4 |
will be conducted when | 4 |
kept for at least | 4 |
blood gas determination via | 4 |
with high risk of | 4 |
treatment for patients with | 4 |
sample size calculation is | 4 |
statistical methods to handle | 4 |
liver and kidney failure | 4 |
a causal relationship between | 4 |
rater reliability of ctcae | 4 |
are provided in the | 4 |
and whether the patient | 4 |
primary end point is | 4 |
be made available in | 4 |
ministry of health and | 4 |
zealand clinical trial registry | 4 |
determine the effect of | 4 |
of participants will be | 4 |
signed and dated by | 4 |
national institute for health | 4 |
the findings of this | 4 |
quality of life of | 4 |
or other medical intervention | 4 |
be recorded as an | 4 |
of secondary outcomes will | 4 |
study is conducted in | 4 |
be stored at the | 4 |
other treatment will be | 4 |
inclusion in the study | 4 |
to this article as | 4 |
obstructive pulmonary disease in | 4 |
in line with the | 4 |
of chronic lung disease | 4 |
after this explanation and | 4 |
very low birth weight | 4 |
in combination with the | 4 |
efficacy of the use | 4 |
iv injection on day | 4 |
a cox proportional hazards | 4 |
be conducted as a | 4 |
the efficacy of the | 4 |
they would like to | 4 |
controlled trial is to | 4 |
with moderate to severe | 4 |
duration of the trial | 4 |
main secondary outcome is | 4 |
in the outpatient setting | 4 |
once deemed clinically appropriate | 4 |
as a random effect | 4 |
vaccination cannot be confirmed | 4 |
in case of a | 4 |
an urgent need for | 4 |
the definition of serious | 4 |
icu length of stay | 4 |
take part in the | 4 |
saes if evaluated as | 4 |
if evaluated as suspected | 4 |
interim analysis of the | 4 |
by the research nurse | 4 |
to a maximum of | 4 |
the details of the | 4 |
in the early stages | 4 |
presentation consistent with covid | 4 |
ciprofloxacin mg kg twice | 4 |
standards of reporting trials | 4 |
workers with high risk | 4 |
the start of randomization | 4 |
at the timepoints indicated | 4 |
skills to support health | 4 |
the study intervention caused | 4 |
ml of whole blood | 4 |
the early stages of | 4 |
will be collected during | 4 |
intravenous sargramostim mcg m | 4 |
due to the use | 4 |
have no role in | 4 |
the following events occurring | 4 |
in the development of | 4 |
red blood cell hb | 4 |
will be obtained by | 4 |
in its design and | 4 |
the investigators will be | 4 |
date of the first | 4 |
information about the study | 4 |
based on the following | 4 |
trial steering committee d | 4 |
of antibiotic treatment for | 4 |
if vaccination cannot be | 4 |
that the patient is | 4 |
on behalf of the | 4 |
to improve hypertension control | 4 |
of secondary haemophagocytic lymphohistiocytosis | 4 |
prognosis of vestibular dysfunction | 4 |
should be recorded in | 4 |
an arterial blood gas | 4 |
determination via arterial puncture | 4 |
of patients showing more | 4 |
or corticosteroid dose equivalents | 4 |
will be conducted using | 4 |
included in the analysis | 4 |
for no more than | 4 |
the final version to | 4 |
for two independent samples | 4 |
study by the treating | 4 |
treatment and for at | 4 |
outcome of the pregnancy | 4 |
study drug will be | 4 |
the global burden of | 4 |
the pwd and the | 4 |
this intervention is measuring | 4 |
as well as other | 4 |
of good clinical practice | 4 |
who clinical improvement ordinal | 4 |
of mechanical ventilation at | 4 |
to halt the progression | 4 |
after initiation of ravulizumab | 4 |
be assigned a unique | 4 |
and or analyzed during | 4 |
for a minimum of | 4 |
progression to respiratory failure | 4 |
care model for breast | 4 |
study was approved by | 4 |
for important intellectual content | 4 |
to alexion within hours | 4 |
that event meets criteria | 4 |
inclusion of the first | 4 |
total of patients will | 4 |
communication skills to support | 4 |
improve outcome in elderly | 4 |
group and in the | 4 |
the date of the | 4 |
first h ketamine will | 4 |
all other treatment will | 4 |
it is important to | 4 |
unexpected and drug related | 4 |
before entry to the | 4 |
to the kfsh rc | 4 |
in blocks of unknown | 4 |
ml of venous blood | 4 |
measuring blood cytokine and | 4 |
would like to acknowledge | 4 |
during the study intervention | 4 |
was registered on april | 4 |
gas determination via arterial | 4 |
will be taken at | 4 |
institute for health research | 4 |
will be expressed as | 4 |
the source documents and | 4 |
and the final allocation | 4 |
the study team and | 4 |
be identified by a | 4 |
for a total of | 4 |
current version of the | 4 |
saudi food and drug | 4 |
the principal investigators will | 4 |
and approved by the | 4 |
blood cytokine and chemokine | 4 |
is measuring oxygenation after | 4 |
anaesthesia with an endotracheal | 4 |
patients in the intervention | 4 |
serum blood sample x | 4 |
sensorineural hearing loss the | 4 |
be reviewed by the | 4 |
to measure the effectiveness | 4 |
be used for the | 4 |
in addition to standard | 4 |
as soon as the | 4 |
group will receive the | 4 |
they should continue antibiotic | 4 |
methods in analysis to | 4 |
the general data protection | 4 |
of at least one | 4 |
hospital length of stay | 4 |
the treating physician will | 4 |
effects of synbiotic supplementation | 4 |
to evaluate the safety | 4 |
control program in argentina | 4 |
administration of study drug | 4 |
septoplasty versus medical management | 4 |
will be returned to | 4 |
for the prevention and | 4 |
of the last patient | 4 |
of the sponsor and | 4 |
lung injury and the | 4 |
outcome analysis will be | 4 |
and the ethics committee | 4 |
to the intervention group | 4 |
on the prevention of | 4 |
will receive jwby formulas | 4 |
is defined as follows | 4 |
months prior to the | 4 |
received approval from the | 4 |
mic is determined for | 4 |
the critical care setting | 4 |
and the decision to | 4 |
will be the first | 4 |
pour les patients du | 4 |
positive samples will be | 4 |
proposed intervention is that | 4 |
the target sample size | 4 |
to the study protocol | 4 |
according to local clinical | 4 |
consequences of acute respiratory | 4 |
participants will be randomized | 4 |
general anaesthesia with an | 4 |
administration once they are | 4 |
meeting the inclusion criteria | 4 |
is a hospital based | 4 |
on day patients will | 4 |
for all patients who | 4 |
satisfying responses to all | 4 |
informed consent was obtained | 4 |
on invasive mechanical ventilation | 4 |
of pao fio and | 4 |
the use of study | 4 |
any statistical methods to | 4 |
of breast cancer survivors | 4 |
and receiving satisfying responses | 4 |
in relation to fio | 4 |
an allocation ratio of | 4 |
data will be recorded | 4 |
he or she has | 4 |
increase in antibody titre | 4 |
exclusion criteria will be | 4 |
recorded in the crf | 4 |
recherche impliquant la personne | 4 |
pao fio and through | 4 |
the recommended dose of | 4 |
reliability and validity of | 4 |
will be administered enoxaparin | 4 |
will be made by | 4 |
lung injury induced by | 4 |
composition of the coordinating | 4 |
sign the informed consent | 4 |
number of weeks during | 4 |
latest version of the | 4 |
outcome in elderly patients | 4 |
the patient does not | 4 |
australian new zealand clinical | 4 |
mg kg every h | 4 |
days after the onset | 4 |
investigator or designee will | 4 |
the results will be | 4 |
when patients are vaccinated | 4 |
the use of anti | 4 |
be collected and processed | 4 |
a high incidence of | 4 |
infusion as an analgo | 4 |
placebo in healthcare workers | 4 |
healthcare workers with high | 4 |
progression of disease requiring | 4 |
bronchiectasis exacerbations in children | 4 |
fatal saes if evaluated | 4 |
sufficient time to considerer | 4 |
patients will be censored | 4 |
to stop the trial | 4 |
collect peripheral blood serum | 4 |
be conducted in the | 4 |
trial with blinded outcome | 4 |
subgroup analyses will be | 4 |
safety profile of the | 4 |
the fifth affiliated hospital | 4 |
daily for days as | 4 |
treatments directed at improving | 4 |
research council of norway | 4 |
is any untoward medical | 4 |
will be done on | 4 |
in children with bronchiectasis | 4 |
days or until discharge | 4 |
after no more than | 4 |
at and weeks post | 4 |
two large cantonal hospitals | 4 |
must be documented on | 4 |
whether or not considered | 4 |
patients who received the | 4 |
in the form of | 4 |
of acute respiratory and | 4 |
will receive the standard | 4 |
and cd t cells | 4 |
be excluded from the | 4 |
on restoring lung homeostasis | 4 |
during an epidemic period | 4 |
adverse event which is | 4 |
the database will be | 4 |
or significant disability incapacity | 4 |
patients with bubonic plague | 4 |
of the end of | 4 |
be performed at baseline | 4 |
ravulizumab treatment and for | 4 |
the patient has any | 4 |
mechanical ventilatory support within | 4 |
samples will be processed | 4 |
first h after randomization | 4 |
x x b x | 4 |
least months from the | 4 |
on the ordinal scale | 4 |
with the data protection | 4 |
a protocol for a | 4 |
clinically appropriate by the | 4 |
least weeks after meningococcal | 4 |
collected as part of | 4 |
received as part of | 4 |
consent will be accepted | 4 |
iv sargramostim mcg m | 4 |
the secondary objectives are | 4 |
treatment through assessment of | 4 |
by the medical ethics | 4 |
the completion of the | 4 |
admitted to the covid | 4 |
event meets criteria for | 4 |
methods to handle missing | 4 |
two groups of patients | 4 |
blocks of unknown size | 4 |
patients in this group | 4 |
progression from manageable acute | 4 |
the exclusion criteria are | 4 |
continue antibiotic prophylaxis for | 4 |
max mg per dose | 4 |
at any time without | 4 |
mechanical ventilation at day | 4 |
principles of the declaration | 4 |
conducted according to the | 4 |
in a timely manner | 4 |
taking care of covid | 4 |
pharmaceuticals for human use | 4 |
days as a nebulized | 4 |
processing of personal data | 4 |
after receiving full explanation | 4 |
line or study center | 4 |
activation of immune cells | 4 |
unexpected serious adverse reaction | 4 |
as an adjunct to | 4 |
as this is a | 4 |
considered related to the | 4 |
the progression of the | 4 |
outcome is time to | 4 |
stored in accordance with | 4 |
and standard treatment parallel | 4 |
defined as the last | 4 |
blinded to the treatment | 4 |
presented in combination with | 4 |
time to considerer the | 4 |
the hypothesis that the | 4 |
food and drug authority | 4 |
quality of life and | 4 |
will be identified by | 4 |
standard treatment parallel control | 4 |
partial pressure of arterial | 4 |
participated in the study | 4 |
point category ordinal scale | 4 |
if received as part | 4 |
numbers to be randomized | 4 |
during the primary evaluation | 4 |
analysis for the global | 4 |
will be performed before | 4 |
after completion of the | 4 |
the latest version of | 4 |
or she will be | 4 |
day patients will receive | 4 |
optional edta blood sample | 4 |
a trial of versus | 4 |
the outcomes will be | 4 |
calculated from the onset | 4 |
electronic randomization will be | 4 |
indigenous infants with bronchiolitis | 4 |
measuring oxygenation after days | 4 |
a systematic analysis for | 4 |
case of lost to | 4 |
of patients infected with | 4 |
a serious adverse reaction | 4 |
blood will be collected | 4 |
the primary outcome of | 4 |
will be given in | 4 |
may switch to oral | 4 |
the nih program officer | 4 |
to support health behaviour | 4 |
be considered as a | 4 |
will be censored in | 4 |
to swallow or once | 4 |
in indigenous australian infants | 4 |
the study is conducted | 4 |
at the baseline visit | 4 |
of the principal investigator | 4 |
will be performed after | 4 |
to detect differences in | 4 |
of acute lung injury | 4 |
the first h ketamine | 4 |
will continue to receive | 4 |
assess the effect of | 4 |
a data safety monitoring | 4 |
time to next exacerbation | 4 |
be used to calculate | 4 |
recorded as an ae | 4 |
date data from the | 4 |
patients with bloodstream infection | 4 |
proportion of patients showing | 4 |
more than days after | 4 |
effects will be presented | 4 |
be collected from the | 4 |
will be entered into | 4 |
years or older with | 4 |
writing of the report | 4 |
the hypothesis of the | 4 |
to improve outcome in | 4 |
the primary analysis is | 4 |
and two large cantonal | 4 |
accompanying person from the | 4 |
reported in accordance with | 4 |
the danish medicines agency | 4 |
an investigational medicinal product | 4 |
appropriate by the treating | 4 |
initiating ravulizumab treatment and | 4 |
according to our local | 4 |
sargramostim mcg twice daily | 4 |
be presented in combination | 4 |
this study will also | 4 |
via arterial puncture will | 4 |
the study protocol has | 4 |
profile of the study | 4 |
final version to be | 4 |
the presence of a | 4 |
be considered to have | 4 |
hypothesis of the proposed | 4 |
block size will be | 4 |
of the study drugs | 4 |
adherence and any statistical | 4 |
the queen elizabeth hospital | 4 |
the best of our | 4 |
the glasgow coma scale | 4 |
epidemiological impact of tirs | 4 |
to protect the rights | 4 |
two consecutive blood gas | 4 |
if he or she | 4 |
or once deemed clinically | 4 |
women of childbearing potential | 4 |
mmhg in two consecutive | 4 |
there are no plans | 4 |
the rest of the | 4 |
cytokine and chemokine levels | 4 |
admitted to specialized covid | 4 |
for days as a | 4 |
arterial puncture will be | 4 |
had no role in | 4 |
patients randomized to the | 4 |
of the first patients | 4 |
complications to improve outcome | 4 |
diversity of respiratory viruses | 4 |
for the global burden | 4 |
they are able to | 4 |
ambulatory patients aged or | 4 |
to reduce the incidence | 4 |
daily until the day | 4 |
during the months of | 4 |
mcg twice daily for | 4 |
primary outcome is time | 4 |
are able to swallow | 4 |
bsc best supportive care | 4 |
in a subject to | 4 |
to initiating ravulizumab treatment | 4 |
for people with dementia | 4 |
support health behaviour change | 4 |
or the use of | 4 |
ventilation or high flow | 4 |
management of venous thromboembolism | 4 |
end of the primary | 4 |
criteria for a susar | 4 |
through measurement of the | 4 |
the time of randomization | 4 |
number of days free | 4 |
we will include patients | 4 |
different peep levels during | 4 |
use of budesonide formoterol | 4 |
willing to provide informed | 4 |
and the consent form | 4 |
jia wei bushen yiqi | 4 |
fourfold increase in antibody | 4 |
the remainder of the | 4 |
once they are able | 4 |
as a function of | 4 |
has been reported in | 4 |
affiliations we would like | 4 |
the randomization will be | 4 |
be analysed according to | 4 |
informed consent to participate | 4 |
treatment will be unchanged | 4 |
information will be recorded | 4 |
informed consent is obtained | 4 |
that provides the imp | 4 |
be offered to the | 4 |
final allocation will be | 4 |
months after treatment with | 4 |
randomized to receive either | 4 |
between the study intervention | 4 |
oxygenation after days of | 4 |
including but not limited | 4 |
will be given the | 4 |
blood sample x ml | 4 |
mean difference in score | 4 |
au score odoratest jours | 4 |
addition to standard care | 4 |
ten days or until | 4 |
implementation of the intervention | 4 |
reduce the morbidity of | 4 |
documentation in hospital records | 4 |
or discharge from the | 4 |
asthma exacerbations per year | 4 |
person from the same | 4 |
detailed description of the | 4 |
local clinical practice protocols | 4 |
swallow or once deemed | 4 |
the trial is designed | 4 |
average red blood cell | 4 |
he or she will | 4 |
after days of inhaled | 4 |
will have no role | 4 |
the study consists of | 4 |
affiliated hospital of sun | 4 |
national institutional review board | 4 |
using a t test | 4 |
measurements of oxygen saturation | 4 |
the risk of death | 4 |
awareness that event meets | 4 |
from manageable acute hypoxic | 4 |
sided significance level of | 4 |
and on day patients | 4 |
will be recruited in | 4 |
measure the effectiveness of | 4 |
systematic analysis for the | 4 |
performed according to the | 4 |
about the study and | 4 |
within days of enrolment | 4 |
halt the progression from | 4 |
the treatment group and | 4 |
a part of the | 4 |
we would need patients | 4 |
the first dose of | 4 |
or a fourfold increase | 4 |
burden of disease study | 4 |
is in line with | 4 |
for days or until | 4 |
study drugs will be | 4 |
the patient and the | 4 |
any combination of these | 4 |
will be collected by | 4 |
infection in reducing their | 4 |
an alternative explanation is | 4 |
is to test the | 4 |
alone in patients with | 4 |
the final allocation will | 4 |
and development of the | 4 |
not expected to survive | 4 |
with hydroxychloroquine against placebo | 4 |
acute generalized exanthematous pustulosis | 4 |
followed by ciprofloxacin mg | 4 |
dans la prise en | 4 |
is the most common | 4 |
days following awareness that | 4 |
invasive or invasive mechanical | 4 |
of complications to improve | 4 |
explanation and before entry | 4 |
physician will have the | 4 |
will receive placebo plus | 4 |
asked to sign icf | 4 |
this explanation and before | 4 |
to detect a difference | 4 |
of the proposed intervention | 4 |
will be eligible to | 4 |
adjusting for the following | 4 |
will ensure that the | 4 |
of care for the | 4 |
progression of the disease | 4 |
initiate iv sargramostim mcg | 4 |
respiratory exacerbations by day | 4 |
patients will only be | 4 |
will participate in the | 4 |
the case of lost | 4 |
the data from the | 4 |
that the incidence of | 4 |
of the primary and | 4 |
an adverse event is | 4 |
be assessed by the | 4 |
adverse event which might | 4 |
will be in accordance | 4 |
following awareness that event | 4 |
oral administration once they | 4 |
the american society of | 4 |
the option to initiate | 4 |
be reported by the | 4 |
from the same household | 4 |
seroconversion or a fourfold | 4 |
be in blocks of | 4 |
for both treatment groups | 4 |
will be constructed using | 4 |
the patient should receive | 4 |
randomized and standard treatment | 4 |
of the use of | 4 |
patients will be informed | 4 |
clinical trial with blinded | 4 |
the primary objective of | 4 |
event in which the | 4 |
be followed up by | 4 |
be performed using sas | 4 |
saes will be reported | 4 |
clinical improvement ordinal score | 4 |
prevention of complications to | 4 |
combination of lopinavir ritonavir | 4 |
questions and receiving satisfying | 4 |
atorvastatin with conventional therapy | 4 |
creatinine clearance ml min | 4 |
during endoscopic retrograde cholangiopancreatography | 4 |
from patients randomized to | 4 |
will be in blocks | 4 |
who consent to participate | 4 |
in at least two | 4 |
the progress of the | 4 |
intervention is measuring oxygenation | 4 |
of technical requirements for | 4 |
for more than h | 4 |
a dose of mg | 4 |
and dated by the | 4 |
reviewed and approved by | 4 |
will be imputed using | 4 |
hours after becoming aware | 4 |
calendar days following awareness | 4 |
data must be collected | 4 |
in preterm infants with | 4 |
of neutrophil extracellular traps | 4 |
in randomised controlled trials | 4 |
from the hospital or | 4 |
lead to improved short | 4 |
kg day in the | 4 |
parameters x a x | 4 |
the national cancer institute | 4 |
group will be administered | 4 |
will not be considered | 4 |
sample will be taken | 4 |
the dsmb will meet | 4 |
will be regarded as | 4 |
sponsor and principal investigator | 4 |
patient should receive prophylactic | 4 |
soc group without sarilumab | 4 |
received sufficient time to | 4 |
we will perform daily | 4 |
to local clinical practice | 4 |
prophylaxis for at least | 4 |
than calendar days following | 4 |
fifth affiliated hospital of | 4 |
one of the most | 4 |
able to swallow or | 4 |
by means of the | 4 |
performed at baseline and | 4 |
baseline and at and | 4 |
the study team will | 4 |
of this trial will | 4 |
by the local principal | 4 |
is associated with covid | 4 |
the day of the | 4 |
all authors contributed to | 4 |
ventilatory support within the | 4 |
weeks after meningococcal vaccination | 4 |
included in the fas | 4 |
du code de la | 4 |
may be associated with | 4 |
persistent or significant disability | 4 |
guardian next of kin | 4 |
on a global scale | 4 |
of the adverse event | 4 |
will be offered the | 4 |
after becoming aware of | 4 |
of weeks during which | 4 |
be included in an | 4 |
be performed according to | 4 |
be taken into account | 4 |
patients with medical illnesses | 4 |
after inclusion of the | 4 |
the sponsor and principal | 4 |
all patients have completed | 4 |
have a causal relationship | 4 |
will be reported in | 4 |
if there is a | 4 |
serious adverse event is | 4 |
nature of the study | 4 |
switch to oral administration | 4 |
this is a multi | 4 |
and no treatment that | 4 |
be analyzed using the | 4 |
number of aes saes | 4 |
peripheral blood serum to | 4 |
will take place in | 4 |
from the onset of | 4 |
every hours in the | 4 |
the study is being | 3 |
patients randomized in the | 3 |
and compared using a | 3 |
primary outcome of this | 3 |
the incidence of bpd | 3 |
and data usage has | 3 |
number of desaturation events | 3 |
intervention and control group | 3 |
task is experienced by | 3 |
a wide range of | 3 |
participants or their legal | 3 |
family environment or support | 3 |
attempt to contact the | 3 |
will be compared in | 3 |
person visit if the | 3 |
problems with diagnostic sensitivity | 3 |
subjects will be recruited | 3 |
agreed to participate in | 3 |
failures are defined as | 3 |
the incidence of symptomatic | 3 |
assessing the efficacy of | 3 |
with nasal obstruction associated | 3 |
be used to measure | 3 |
failure fulfilling criteria for | 3 |
an event in which | 3 |
in patients undergoing ercps | 3 |
on ageing and health | 3 |
data analysis will be | 3 |
in the medical record | 3 |
and the results of | 3 |
collection in private rooms | 3 |
the first infusion of | 3 |
the new p f | 3 |
the study will also | 3 |
mechanically ventilated icu patients | 3 |
component of the primary | 3 |
can only be enrolled | 3 |
assigned to the study | 3 |
cov infection treated with | 3 |
accordance with the data | 3 |
any clinically relevant bleeding | 3 |
standard hygiene requirements at | 3 |
participating in this clinical | 3 |
patient and public involvement | 3 |
to reduce the morbidity | 3 |
clinical utilisation of respiratory | 3 |
how burdensome the task | 3 |
and processed with adequate | 3 |
and with highly suspect | 3 |
versus standard of care | 3 |
is approved by the | 3 |
radiologist and pulmonary physician | 3 |
optimum level of peep | 3 |
causal relationship with the | 3 |
or equivalent cs dose | 3 |
of the coordinating centre | 3 |
at the study site | 3 |
the evaluation of the | 3 |